Literature DB >> 12644330

Stimulating pharmaceutical research and development for neglected diseases.

Monique F Mrazek1, Elias Mossialos.   

Abstract

New vaccines and drug treatments are needed for tackling the neglected diseases (NDs) of poor countries. These diseases are associated with high levels of mortality and/or morbidity, but lack appropriate vaccines and drug treatments because of bacterial resistance, toxicity, long-treatment protocols, problems with administration or because none are available. Current initiatives directed at research and development (R&D) of NDs are being led predominantly by the governmental, inter-governmental and private not-for-profit sectors implemented by way of public-private partnerships. Push and pull mechanisms targeted at the pharmaceutical industry have also been proposed as another way to stimulate R&D of NDs; however, these should be viewed with some caution. Stimulating R&D for NDs is important as part of a wider long-term public health strategy and must be addressed simultaneously with resolving more immediate problems of access to medicines and health system sustainability in less developed countries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644330     DOI: 10.1016/s0168-8510(02)00138-0

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  6 in total

Review 1.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

2.  Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

Authors:  Claudimar Pereira da Veiga; Cássia Rita Pereira da Veiga; Jansen Maia Del Corso; Wesley Vieira da Silva
Journal:  Int J Environ Res Public Health       Date:  2015-08-12       Impact factor: 3.390

3.  Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?

Authors:  Frank Mueller-Langer
Journal:  Health Econ Policy Law       Date:  2013-01-24

4.  Threats from emerging and re-emerging neglected tropical diseases (NTDs).

Authors:  Tim K Mackey; Bryan A Liang
Journal:  Infect Ecol Epidemiol       Date:  2012-08-01

5.  Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.

Authors:  David M Brogan; Elias Mossialos
Journal:  Global Health       Date:  2013-11-07       Impact factor: 4.185

Review 6.  Innovation in neglected tropical disease drug discovery and development.

Authors:  Hong-Bo Weng; Hai-Xia Chen; Ming-Wei Wang
Journal:  Infect Dis Poverty       Date:  2018-06-18       Impact factor: 4.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.